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Available online 18 May 2016Clinical trials shows that remote ischemic preconditioning (IPC) can protect against contrast induced nephropa-
thy (CIN) in riskypatients, however, the exactmechanism is unclear. In this study,we exploredwhether renalase,
an amine oxidase that has been previously shown to mediate reno-protection by local IPC, would also mediate
the same effect elicited by remote IPC in animal model. Limb IPC was performed for 24 h followed by induction
of CIN. Our results indicated that limb IPC prevented renal function decline, attenuated tubular damage and re-
duced oxidative stress and inﬂammation in the kidney. All those beneﬁcial effects were abolished by silencing
of renalase with siRNA. This suggests that similar to local IPC, renalase is also critically involved in limb IPC-
elicited reno-protection. Mechanistic studies showed that limb IPC increased TNFα levels in the muscle and
blood, and up-regulated renalase and phosphorylated IκBα expression in the kidney. Pretreatment with TNFα
antagonist or NF-κB inhibitor, largely blocked renalase expression. Besides, TNFα preconditioning increased ex-
pression of renal renalase in vivo and in vitro, and attenuated H2O2 induced apoptosis in renal tubular cells. Col-
lectively, our results suggest that limb IPC-induced reno-protection in CIN is dependent on increased renalase
expression via activation of the TNFα/NF-κB pathway.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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TNFα1. Introduction
Contrast induced nephropathy (CIN) has become one of the leading
causes of hospital-acquired acute kidney injury (AKI) (Nash et al., 2002)
as contrast agents are widely utilized in clinical diagnostic and interven-
tional procedures (Asif and Epstein, 2004;Wang et al., 2013). CIN follow-
ing cardiac angiogram or intervention is associated with signiﬁcant
morbidity and mortality, with an in-hospital mortality rate of 20% in un-
selected patients and a 1-year mortality rate of up to 66% (Rihal et al.,
2002; Shlipak et al., 2002; Best et al., 2002). However, there is still no ef-
fective prophylactic regimen available to prevent occurrence of CIN
(Gassanov et al., 2014). Therefore, it is urgent to develop novel strategies
to decrease CIN incidence and to improve clinical outcomes.
Accumulated evidence indicates that CIN is the result of combined di-
rect toxic effects of contrast media and hypoxic renal injury (Sendeski,
2011). Renal ischemia-reperfusion (I/R) injury due to contrast induced200233, China.
), szhuang@lifespan.org
ted to this work equally.
. This is an open access article underhemodynamic alteration of renal blood ﬂow plays a pivotal role in the
pathogenesis of CIN (Evans et al., 2013; Persson et al., 2005). Besides, con-
trastmedia induced production of free oxygen radicals also contributes to
renal tubular cell injury (Pisani et al., 2013). Thus, the strategies for
protecting against hypoxic injury may also be effective for prevention
and treatment of CIN.
Remote ischemic preconditioning (IPC) is deﬁned as temporal epi-
sodes of ischemia of remote organ before a subsequent prolonged I/R in-
jury. It can facilitate other organs to tolerate a more severe injury and to
reduce the extent of distant organ damage. The tissue protective effects
of this approach have been reported in myocardial infarction and AKI
(Przyklenk andWhittaker, 2011;Wever et al., 2011). Limb IPC, one of re-
mote IPC represents a promising approach for clinical intervention, has
been tested in the prevention of CIN in clinic trials and gained encourag-
ing results, especially in patients with a high risk of CIN (Er et al., 2012,
Menting et al., 2015). However, its reno-protective mechanism remains
elusive.
Previous studies have shown that remote IPC is involved in activation
of multifactorial anti-inﬂammatory, neuronal, and humoral signaling
pathways (Gassanov et al., 2014). For example, remote IPC could confer
cardio-protection against ischemia through up-regulating erythropoietinthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2015). EPO preconditioning is also able to protect against cardiac and kid-
ney I/R injury (Gardner et al., 2014). As such, some factors/molecules pro-
duced in the kidneymay play a role in the defensemechanism of remote
IPC. Thus, it will be interesting to identify novel kidney-secreted proteins
contributing to renal protection under remote IPC.
Among numerous candidates that exert a reno-protective effects,
renalase is not only a kidney-originated amine oxidase, but also a mol-
ecule that is subjected to HIF-1 regulation at transcriptional level
(Wang et al., 2015c, Du et al., 2015). It has been documented that
renalase can regulate blood pressure and protect against both heart
and kidney I/R injury (Lee et al., 2013; Wang et al., 2014a, 2014b,
2015a, 2015c; Du et al., 2015, Guo et al., 2014). Our previous study
also demonstrated that exogenous administration of renalasewas effec-
tive in alleviating CIN in rats (Zhao et al., 2015) and that local IPC in-
duced cortex renalase upregulation via HIF-1α dependent mechanism.
Furthermore, renalase plays a vital role in reno-protection of local IPC
against I/R induced AKI (Wang et al., 2015c). In line with our observa-
tions, other studies showed that renalase expression was elevated and
attenuated cardiac injury in mice challenged with cardiac I/R (Du
et al., 2015). Recently, it has been reported that renalase may function
as a pro-survival/growth factor and signals via the receptor plasma
membrane calcium ATPase subtype 4b (PMCA4b) (Wang et al., 2015d,
Guo et al., 2016). Nevertheless, there is no study to address the role of
renalase in remote IPC against kidney I/R injury so far.
In the present study, we examinedwhether renal renalase would be
up-regulated in rats subjected to limb IPC and whether such a remote
IPC-induced increase of renalase expression would contribute to reno-
protective effects in CIN. In addition, we also investigated the potential
mechanisms by which limb IPC regulated renalase expression in the
kidney.
2. Materials and methods
This study was approved by the Animal Care and Ethics Committee
of Shanghai Jiao Tong University Afﬁliated Sixth People's Hospital.
2.1. Reagents, animals and cells
Ioversol was purchased from Hengrui Corp. (Jiangsu, China). N-
nitro-L-arginine methyl ester (L-NAME), indomethacin, tosyl
phenylalanyl chloromethyl ketone (TPCK, a nuclear factor kappa-light-
chain-enhancer of activated B cells, NF-κB inhibitor), pyrrolidineFig. 1. The schema for animal study protocols. a. Limb ischemic preconditioning followed (IP
expression after limb IPC. c. Limb IPC induced renalase expression with TNFα blocking or
randomly divided into desired groups (as showed in the schema) with 6 animals in each groudithiocarbamate (PDTC, an NF-κB inhibitor), 3-(5′-Hydroxymethyl-2′-
furyl)-1-benzyl indazole (YC-1, a HIF-1α inhibitor), and tumor necrosis
factor α (TNFα) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Humira, a TNFα antagonist, was provided by AbbVie (North Chi-
cago, IN, USA). The cholesterol-conjugated speciﬁc renalase siRNAwere
provided by Shanghai Biotend Corp. (Shanghai, China). Male Sprague-
Dawley rats, weighing 200 ± 20 g, were provided by Shanghai Science
Academy animal center (Shanghai, China). All the rats were housed
under controlled conditions of light (12 h dark/12 h light cycle) and
temperature (20–23 °C), and fed with standard diet and tap water.
HK2 cells from ATCC (Rockefeller, MD, USA) were used as a proximal
renal tubular epithelial cell model.
2.2. Rat models of delayed remote IPC and CIN
All the animal experiment protocols were demonstrated in Fig. 1.
Study 1: Limb IPC protects against CIN via renalase (Fig. 1A).
The rats were divided into a sham-operated group (Sham), a remote
IPC group (IPC), a CIN group, an IPC + CIN group, a CIN + Scramble
siRNA group, a CIN + Renalase siRNA group, an
IPC + CIN + Scramble siRNA group and an IPC + CIN + Renalase
siRNA group, N=6 in each group. Remote IPCwas delivered by occlud-
ing hind limb blood ﬂowwith a tightened tourniquet around the upper
thigh for 6 cycles of 10-min occlusion followed by 10-min release under
anesthesia with 50 mg/kg pentobarbital. The limb ischemia was con-
ﬁrmed by pallor and cyanosis of the lower limb below the tourniquet.
CIN was induced similarly to that described previously (Zhao et al.,
2015). Brieﬂy, rats were given a tail vein injection of indomethacin
(10 mg/kg), followed by Ioversol (3 g/kg organically bound iodine)
and L-NAME.
In the IPC + CIN group, CIN were induced at 24 h after limb IPC. In
rats of the CIN + Scramble siRNA group, CIN + Renalase siRNA group,
IPC + CIN + Scramble siRNA group and IPC + CIN + Renalase siRNA
group, a midline laparotomy was performed after anesthetizing with
50 mg/kg pentobarbital. Then, scramble siRNA or renalase siRNA was
injected into the bilateral renal cortex at 12 h before IPC or 38 h before
CIN induction. Rats in the CIN or IPC+CIN groupswere treatedwith the
vehicle of the same volume at the same time points.
Study 2: limb IPC induces renalase expression (Fig. 1B).
Limb IPCwas induced in rats ﬁrst, followed by blood and tissues har-
vested at 6 h, 12 h, and 24 h (N = 6 in each group).C) by contrast-induced renal injury inducing and renalase blocking protocol. b. Renalase
NF-κB or HIF-1 blocking. d. TNFα preconditioning with NF-κB blocking. The rats were
p.
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Rats were divided into Sham group, IPC group, IPC+ Humira group,
IPC + PDTC group and IPC + YC-1 group (N = 6 in each group). Limb
IPC was induced in IPC groups similarly to Study 1. Rats in
IPC + Humira group, IPC + PDTC group, and IPC + YC-1 group were
given an intraperitoneal injection of Humira (1 mg/kg), PDTC
(100 mg/kg) or YC-1 (2 mg/kg) 2 h before IPC, respectively.
Study 4: TNFα induces renalase expression via NF-κB (Fig. 1C).
Rats were divided into Sham group, TNFα group, and TNFα+ PDTC
group (N= 6 in each group). Rats in IPC group received limb IPC induc-
tion. Rats in the TNFα group were given an intravenous injection of
TNFα (0.1 μg/kg) or an intraperitoneal injection of PDTC 2 h before
TNFα administration (Lecour et al., 2005). The tissues were harvested
at 6 h after remote IPC.
2.3. Experiments in vitro
HK2 cells were cultured in K-SFM at 37 °C 5% CO2, supplemented
with 5 ng/ml human recombinant EGF and 0.05 μg/ml bovine pitui-
tary extract. HK2 cells were treated with TNFα to investigate
renalase expression. TPCK was used as an NF-κB inhibitor in vitro.
Besides, to determine whether TNFα preconditioning could protect
against oxidative injury, HK-2 cells were pretreated with vehicle or
TNFα (20 ng/ml) for 6 h and then were exposed to H202
(300 μmol/l) for an additional 12 h.
2.4. Assessment of renal function and oxidative injury
An automatic biochemical analyzer (7600, Hitachi, Japan) was
employed to measure serum creatinine (Scr) and blood urea nitrogen
(BUN) to assess the changes in renal function. Renal levels of
malondialdehyde (MDA) and superoxide dismutase (SOD) were mea-
sured using commercial kits following the manufacturer's protocol
(Nanjing Jiancheng, Nanjing, China).
2.5. Histological injury assessment
The ﬁxed left kidney was embedded in parafﬁn and then was cut
into 3-μm sections. Histological alterations were evaluated by Periodic
acid–Schiff (PAS) staining. The renal injurywas scored using grading tu-
bular necrosis, loss of brush border, cast formation, and tubular dilata-
tion in 10 randomly chosen, non-overlapping ﬁelds. The renal injury
degree was estimated by the following criteria: 0, none; 1, 0–10%; 2,
11–25%; 3, 26–45%; 4, 46–75%; and 5, 76–100%, as described previously
(Melnikov et al., 2002).
TUNEL staining was performed using an in situ cell death detec-
tion kit (Roche Diagnostics, Mannheim, Germany) according to the
manufacturer's instructions. Numbers of TUNEL-positive tubular
cells were quantiﬁed by counting 10 randomly chosen, non-
overlapping ﬁelds per slide.
2.6. Macrophage inﬁltration in renal tissues
Immunohistochemistry was performed with an anti-CD68 antibody
(Abcam, Cambridge, MA, USA) to identify inﬁltrated macrophages in
renal tissue as described previously (Wang et al., 2015b).
2.7. Quantitative real-time PCR
Total RNA from HK2 cells or kidney tissues was isolated using
Trizol (Invitrogen, Carlsbad, CA, USA). mRNA levels were quantiﬁed
using one-step real-time PCR with Taqman chemistry (Applied
Biosystems, Foster City, CA, USA) as described previously (Wang
et al., 2014a). 18S rRNAs were used as internal normalizer formRNAs. The primers for rat MCP-1 were 5′
ATGCAGGTCTCTGTCACG3′ (forward) and 5′-CTAGTTCTCTGTCATA
CT-3′ (reverse); the primers of rat renalase and human renalase
were 5′-AAAGAGGGAGATGGGTTAGTAGTGG-3′ (forward), 5′-TCGG
TTCTGAGGAGGATGGAG-3′ (reverse), and 5′-GAAAAATCATTGCAGC
CTCTCA-3′ (forward), 5′-AAGTTCTGCCTGTGCCTGTGTA-3′ (reverse),
respectively.
2.8. Western blot analysis
Renalase and NF-κB levels were analyzed using western blot sim-
ilar to that described previously (Wang et al., 2014a). The primary
antibodies, anti-renalase, anti-caspase3, anti-Phospho-IκBα
(Ser32) and anti-GAPDH were from Abcam (Cambridge, MA, USA)
(rabbit anti-renalase monoclonal antibody, 1:500 dilution), Cell Sig-
naling Technology (Danvers, MA, USA) (rabbit anti-Phospho-IκBα
(Ser32) monoclonal antibody, 1:500 dilution; rabbit anti-caspase3
polyclonal antibodies, 1:1000 dilution) and Santa Cruz Biotechnolo-
gy (Santa Cruz, CA, USA) (goat anti-GAPDH polyclonal antibody,
1:5000 dilution), respectively. The secondary antibodies were from
Santa Cruz (horseradish peroxidase–conjugated goat anti-mouse
and anti-rabbit IgG).
2.9. Statistical analysis
The statistical software SPSS (Ver. 18.0) (USA) was used for data
analysis. All the data were expressed as mean ± standard error
(SEM). One-way ANOVA with Sidak compensation was employed
for parametric data and Kruskal-Wallis with Dunn’ compensation
for non-parametric data comparison. A value of P b 0.05 was consid-
ered signiﬁcant.
3. Results
3.1. Limb IPC protects against CIN
As shown in Fig. 2, the rats exhibited signiﬁcant exacerbation of
renal function 24 h in CIN groups after administration of contrast
agent, as indicated by remarkable increase of Scr and BUN. Limb
IPC signiﬁcantly attenuated the renal impairment (Scr, limb
IPC+CIN vs. CIN, P b 0.05; BUN, limb IPC+CIN vs. CIN, P b 0.05). His-
tological analysis further demonstrated that the renal tubular de-
tachment, foamy degeneration, and necrosis of tubular cells were
less severe in limb IPC + CIN group compared with CIN group
(Fig. 3a). Meanwhile, limb IPC reduced the pathological tubular inju-
ry score in CIN (Fig. 3b). Furthermore, limb IPC decreased renal MDA
levels and increased SOD levels after Ioversol injection (limb
IPC + CIN vs. CIN, P b 0.05) (Fig. 4). Finally, limb IPC also signiﬁcantly
reduced tubular cell apoptosis and CD68-positive macrophage inﬁl-
tration to the injured kidney (limb IPC + CIN vs. CIN, P b 0.05) as
shown in Figs. 5 and 6. These data indicated that limb IPC was able
to protect against Ioversol-induced kidney injury via mitigating apo-
ptosis, reducing inﬂammation and attenuating oxidative stress.
3.2. Limb IPC-mediated reno-protection against CIN is dependent on
renalase upregulation
To determine whether renalase would be involved in the reno-
protective effects of limb IPC, siRNA was administrated to knock
down renal renalase prior to CIN induction. As shown in Fig. S1,
siRNA injection led to signiﬁcant decrease of renalase mRNA and
protein expression. We observed that all the aforementioned renal
protective effects offered by limb IPC including improvement of
renal function and histological injury, were inhibited by renalase
downregulation (Figs. 2–6). This suggests that limb IPC induced
Fig. 2. Knocking down renalase exacerbates contrast induced renal injury following limb ischemic preconditioning. Contrast-induced nephropathy (CIN) was induced in rats 24 h after
limb ischemic preconditioning and at 24 h after CIN, blood and tissues were collected for further analysis. a. Blood urea nitrogen. b. Serum creatinine. Sham, sham-operated control
group; CIN, contrast induced nephropathy group without Iimb IPC; CIN + Scramble siRNA, contrast induced nephropathy group with scramble siRNA injection; CIN + Renalase siRNA,
contrast induced nephropathy group with renalase siRNA injection; IPC + CIN, contrast induced nephropathy group following limb IPC; IPC + CIN + Scramble siRNA, contrast
induced nephropathy group following limb IPC with scramble siRNA injection; IPC + CIN + Renalase siRNA, contrast induced nephropathy group following limb IPC with renalase
siRNA injection. N= 6, ⁎P b 0.01 versus Sham; #P b 0.05 versus CIN; ▲P b 0.05 versus IPC + CIN + Scramble siRNA.
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limb IPC against CIN.3.3. Limb IPC leads to increased TNFα levels in the muscle and blood, and
elevated expression of renal cortical renalase
Both renalase mRNA and protein levels were increased at 6 h (limb
IPC vs. Sham, P b 0.05) and 12 h (limb IPC vs. Sham, P b 0.05) and renalase
protein also increased at 24 h (limb IPC vs. Sham, P b 0.05) after limb is-
chemia (Fig. 7a–b). The maximum levels of renalase mRNA and protein
were observed at 6 h and 24 h, respectively. Additionally, both muscular
TNFα mRNA and serum TNFα were up-regulated at 6 h (limb IPC vs.
Sham, P b 0.05) after limb ischemia (Fig. 7c–d).Fig. 3. Renal morphological changes are worsened after renalase inhibition in CIN rats followin
after limb ischemic preconditioning and at 24 h after CIN, tissues were collected for further ana
pictures, 400×, PAS). b. Tubular injury scoring. Sham, sham-operated control group; CIN, contra
nephropathy group with scramble siRNA injection; CIN + Renalase siRNA, contrast induced ne
group following limb IPC; IPC + CIN + Scramble siRNA, contrast induced nephropathy group
induced nephropathy group following limb IPC with renalase siRNA injection. All values a
▲P b 0.05 versus IPC + CIN + Scramble siRNA.3.4. Limb IPC induces renalase up-regulation through activation of the
TNFα/NF-κB pathway
Since the maximum expression of renalase mRNA was observed at
6 h after limb ischemia, we carried out a set of experiments at this
time point to investigate whether NF-κB and HIF-1 pathways were in-
volved in limb IPC-induced renalase upregulation in the kidney. As
shown in Fig. 7f, expression of cortical renalase protein was increased
dramatically 6 h after limb ischemia compared with sham-operated an-
imals. Coincidentally, phospho-inhibitor of kappa B (IκBα), as the indi-
cator of activation of NF-κB, was also increased in renal cortex after limb
IPC (Fig. 7e). Pretreatment with either Humira (Scheinfeld, 2003), an
antagonist of TNFα, or pyrrolidinedithiocarbamate (PDTC) (Zhou
et al., 1999), a speciﬁc NF-κB inhibitor, abolished elevation ofg limb ischemic preconditioning. Contrast induced nephropathy was induced in rats 24 h
lysis. a. Renal histological alterations by periodic acid–Schiff (PAS) staining (representative
st induced nephropathy groupwithout Iimb IPC; CIN+ Scramble siRNA, contrast induced
phropathy group with renalase siRNA injection; IPC + CIN, contrast induced nephropathy
following limb IPC with scramble siRNA injection; IPC + CIN + Renalase siRNA, contrast
re presented as means ± SEM (N = 6). ⁎P b 0.01 versus Sham; #P b 0.05 versus CIN;
Fig. 4. Alterations of renal malondialdehyde and superoxide dismutase levels in CIN rats following limb ischemic preconditioning. Contrast induced nephropathywas induced in rats 24 h
after limb ischemic preconditioning and at 24 h after CIN, tissues were collected for further analysis. a. Renalmalondialdehyde (MDA). b. Renal superoxide dismutase (SOD). Sham, sham-
operated control group; CIN, contrast induced nephropathy group without Iimb IPC; CIN + Scramble siRNA, contrast induced nephropathy group with scramble siRNA injection;
CIN + Renalase siRNA, contrast induced nephropathy group with renalase siRNA injection; IPC + CIN, contrast induced nephropathy group following limb IPC; IPC + CIN + Scramble
siRNA, contrast induced nephropathy group following limb IPC with scramble siRNA injection; IPC + CIN + Renalase siRNA, contrast induced nephropathy group following limb IPC
with renalase siRNA injection. All values are presented as means ± SEM (N= 6). ⁎P b 0.01 versus Sham; #P b 0.05 versus CIN; ▲P b 0.05 versus IPC + CIN + Scramble siRNA.
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was no signiﬁcant difference in renalase and phospho-IκBα expression
in CIN rats subjected to YC-1, a speciﬁc HIF-1α inhibitor (Fig. 7e–f).
Taken together, these data indicated that activation of NF-κB, but not
HIF-1α, was responsible for renalase expression in the kidney after
limb IPC. Since limb muscle ischemia can result in the release of TNFα
from injured tissue to the blood and this cytokine is able to induce acti-
vation of NF-κB and renal renalase synthesis, our data thus suggest that
the TNFα/NF-κB pathwaymay be involved in limb IPC induced renalase
upregulation.
3.5. TNFα preconditioning up-regulates renalase in the kidney via activa-
tion of the NF-κB pathway
To directly elucidate the possible role of TNFα in renalase expression
and the NF-κB pathway in this process, we further assessed the effect of
exogenous TNFα on renal renalase and phospho-IκBα expression in rats
and the effect of NF-κB inhibition. Similar to the role of limb IPC, admin-
istration of exogenous TNFα also increased expression levels of renalase
and phospho-IκBα in the kidney at 6 h. Interestingly, TNFα induced
renalase and phospho-IκBα expression were also abolished by PDTC
whereas YC-1 treatment did not show any inhibitory effect on expres-
sion of these two proteins (Fig. 8a–b). Thus, these data enforces the im-
portant role of the TNFα/NF-κB pathway in regulating expression of
renal renalase and further suggests TNFα as the intermediator in linking
limb IPC to renalase upregulation and subsequent renal protection.
3.6. TNFα induces renalase expression in proximal renal tubular epithelial
cells via activation of NF-κB signaling pathway
To further validatewhether TNFαwould act on renal tubular cells to
provoke renalase expression, we examined the effect of TNFα on
renalase and phospho-IκBα expression in cultured HK2 cells, a human
renal proximal tubular cell line. HK2 cellswere exposed to different con-
centrations of TNFα for 6 h, and renalase and phospho-IκBα expression
were then assessed. In agreementwith our animal study, the expression
level of renalase and phospho-IκBα in HK2 cells exposed to a low dose
of TNFα was higher than those without incubation with this cytokine.
Consistently, treatment with tosyl phenylalanyl chloromethyl ketone(TPCK) (Wang et al., 2014a; Zhou et al., 1999), an inhibitor of NF-κB,
also effectively reduced TNFα induced IκBα phosphorylation and
renalase expression in this cell type (Fig. 8c–e). As such, we suggest
that TNFα can stimulate renal tubular cells to produce renalase though
activation of the NF-κB pathway.
3.7. TNFα preconditioning protects against H2O2 cytotoxicity and apoptosis
in HK-2 cells
If TNFα-induced renalase expression is required for renal protection,
preincubaton of renal tubular cells with this cytokine should protect
against cell death in response to acute injury. To test this hypothesis,
we investigated the TNFα preconditioning on H2O2 cytotoxicity in HK-
2 cells. HK2 cells were treated with a low dose of TNFα (10 ng/ml) for
6 h followed by exposure of them to H2O2 for an additional 12 h. As
shown in Fig. 9, H2O2 exposure led to a remarkable cell death as indicat-
ed by increases of LDH release and apoptotic cells in cultures without
TNFα preconditioning, whereas TNFα pretreatment signiﬁcantly de-
creased LDH release and caspase-3 activity.
4. Discussion
In the present study,we demonstrated that remote IPC (limb IPC) al-
leviates the subsequent renal injury induced by contrast media through
the mechanisms associated with anti-apoptosis, anti-inﬂammation and
anti-oxidation. We also found that the reno-protective effects of limb
IPC against CIN are mediated by renalase upregulation. Furthermore,
our results indicate that limb IPC induced renalase expression is regulat-
ed via the TNFα/NF-κB, but not HIF-1 pathway. Thus, we suggest that
remote IPC induced renalase upregulation is critically involved in the
reno-protective effect in CIN.
Remote IPC, especially limb IPC, is a harmless, nonpharmacological
and effective prevention and treatment strategy for I/R injury in many
organs and has beenwidely used in clinical settings. Recent studies sug-
gest that this approach is also effective for prevention of AKI (Wever
et al., 2011) and CIN (Liu et al., 2015). In agreement with previous ani-
mal studies (Liu et al., 2015), we found that limb IPC attenuated deteri-
oration of renal function after Ioversol-induced CIN, which was
accompanied with reduced cell apoptosis, inﬂammation and oxidative
Fig. 5. Renal apoptosis is exacerbated after renalase inhibition in CIN rats following limb ischemic preconditioning. Contrast induced nephropathy was induced in rats 24 h after limb
ischemic preconditioning and at 24 h after CIN, tissues were collected for further analysis. a. Renal histological apoptosis by TUNEL (terminal deoxynucleotidyl transferase dUTP nick
end labeling) staining (representative pictures, 400×, TUNEL staining). b. Semi-quantitative analysis of number of apoptotic cells per ﬁeld. c. Renal cleaved-caspase3 expression. Sham,
sham-operated control group; CIN, contrast induced nephropathy group without Iimb IPC; CIN + Scramble siRNA, contrast induced nephropathy group with scramble siRNA injection;
CIN + Renalase siRNA, contrast induced nephropathy group with renalase siRNA injection; IPC + CIN, contrast induced nephropathy group following limb IPC; IPC + CIN + Scramble
siRNA, contrast induced nephropathy group following limb IPC with scramble siRNA injection; IPC + CIN + Renalase siRNA, contrast induced nephropathy group following limb IPC
with renalase siRNA injection. All values are presented as means ± SEM (N= 6). ⁎P b 0.01 versus Sham; #P b 0.05 versus CIN; ▲P b 0.05 versus IPC + CIN + Scramble siRNA.
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after limb IPC whereas renalase knockdown eliminated the reno-
protection of limb IPC as evidenced by our observations that rats
pretreated with renalase siRNA exhibited more severe tubular injury
and worsen renal function. These results are consistent with our previ-
ous study showing that exogenous renalase administration protected
CIN through anti-oxidation, anti-inﬂammation and anti-apoptosis
mechanisms (Zhao et al., 2015) and suggest that renalase plays a pivotal
role in mediating the reno-protective effect of limb IPC.
Mounting evidence has proved that renalase can mediates
cytoprotection via activating survival-associated signaling such as
Mitogen-activated protein kinase (MAPK) and Protein kinase B (AKT)
(Wang et al., 2014b, 2015d). Recently, it has been reported that inhibi-
tion of renalase signaling has antitumor activity in pancreatic cancer
andmelanoma (Guo et al., 2016). Our previous study also demonstrated
that local IPC-elicited beneﬁcial effects on renal I/R injurywas partly de-
pendent renalase upregulation, which was associated with decreased
apoptosis and oxidative stress. In this study, our ﬁndings conﬁrmed
that renalase plays an essential role in in remote IPC-elicited reno-
protection against CIN, which contributes to a better understanding of
the biological properties of renalase. Renalase, up-regulated under
both local hypoxia and remote IPC, can promote cell survival and pro-
tect against I/R injury.Currently, themechanismbywhich limb IPC induces upregulation of
renal renalase is incomplete clear. Given that remote IPC-activated hu-
moral signaling pathways is involved in the remote organ protection
(Gassanov et al., 2014), the circulating cytokines released from the
preconditioned limb muscle may increase the resistance to hypoxic in-
jury in distant organ (Bonventre, 2012). In this context, several studies
have revealed that lowdose of TNFαhas protective biological properties
against ischemic injury and preconditioningwith TNFα canmimic clas-
sic IPC in a time and dose dependentmanner (Lecour et al., 2002; Smith
et al., 2002), suggesting that TNFαmay serve as a keymediator for limb
IPC to induce reno-protection. This hypothesiswas supported by the fol-
lowing observations: 1) circulating TNFα increased 6 h after limb IPC,
which preceded the expression of renalase in the kidney that occurred
at 24 h after limb IPC; 2) Renalase expression was up-regulated in the
kidney when exogenous TNFα was administered in the animal; 3) low
dose of TNFα treatment increased renalase expression in cultured
renal epithelial cells, which is required for cell survival in response to
oxidant injury; and 4) administration of Humira, a TNFα antagonist,
blocked limb IPC induced renalase upregulation. TNFαmay be released
from ischemic limb into the systemic circulation and then promotes
renalase synthesis in the remote kidney. In line with our observations,
other studies have also indicated that low dose of TNFα can protect
against I/R injury in heart, liver and neural system (Kleinbongard
Fig. 6. Renal inﬁltrating macrophages are increased after renalase inhibition in CIN rats following limb ischemic preconditioning. Contrast induced nephropathy was induced in rats 24 h
after limb ischemic preconditioning and at 24 h after CIN, tissueswere collected for further analysis. a. Renal inﬁltratedmacrophages byCD68 staining (representative pictures, 400×, IHC).
b. Semi-quantitative analysis of number of CD68-positive cells per ﬁeld. c. Renal MCP-1mRNA expression. Sham, sham-operated control group; CIN, contrast induced nephropathy group
without Iimb IPC; CIN+ Scramble siRNA, contrast induced nephropathy groupwith scramble siRNA injection; CIN+ Renalase siRNA, contrast induced nephropathy groupwith renalase
siRNA injection; IPC+ CIN, contrast induced nephropathy group following limb IPC; IPC+ CIN+ Scramble siRNA, contrast induced nephropathy group following limb IPC with scramble
siRNA injection; IPC + CIN + Renalase siRNA, contrast induced nephropathy group following limb IPC with renalase siRNA injection. All values are presented as means ± SEM (N= 6).
⁎P b 0.01 versus Sham; #P b 0.05 versus CIN; ▲P b 0.05 versus IPC + CIN + Scramble siRNA.
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2013).
Nevertheless, how TNFα mediates renal protection has not been
well deﬁned. It is well known that TNFα is a pleiotropic cytokine in-
volved in the regulation of infection, inﬂammation, autoimmune, and
apoptosis (Pasparakis et al., 1996; Karatzas et al., 2014), thus, this cyto-
kinemay play a detrimental role through its pro-inﬂammatory effects in
certain tissues/organs after acute injury. However, since low dose of
TNFα can induce activation ofmultiple signaling pathways that regulate
expression/activation of differentmoleculewith diverse biological func-
tions, it is possible thatmuscular TNFα released during limb IPCmay in-
duce activation of a signaling pathway(s) that triggers expression of a
protective molecule such as renalase. In this context, we observed that
limb IPC-induced renalase upregulationwas accompanied by activation
of NF-κB signaling in the kidney and pretreatmentwith either TNFα an-
tagonist (Humira), or NF-κB inhibitor (PDTC), blocked renalase expres-
sion. Therefore, the NF-κB signaling pathwaymay play an essential role
in transmitting the renal protective signal from TNFα to expression of
some molecules (i.e., renalase) required for renal protection. In support
of this hypothesis, activation of the TNFα/NF-κB signaling pathway has
been reported to mediate survival of several cell types including
cardiomyocytes (Lecour et al., 2005), hepatocytes (Feng et al., 2013)
and neuron (Watters et al., 2011) as well as renal tubular cells asindicated in this study. Interesting, it was been reported that low dose
of TNFα increased cardiomyocytes' tolerance to toxicity of “high
TNFα” (Cacciapaglia et al., 2014). Although we can no rule out the pos-
sibility that limb IPC -induced activation of TNFα signaling pathway
may also causes a deleterious effect, the protective effect of TNFα/NF-
κB signaling observed in the current study suggests that, at least in the
case of CIN, the beneﬁcial effects mediated by this pathway overrides
its deleterious effects to the kidney. Further investigations are needed
to address this issue.
Othermolecules and signaling pathwaysmay also be involved in the
renal protection after limb IPC. Animal and human studies have re-
vealed that transient limb IPC can lead to a rapid increase of serum
EPO (Oba et al., 2015). Increased expression of endogenous EPO or ad-
ministration of exogenous EPO has been reported to play a protective
effect against renal injury induced by diverse stimuli. As such, remote
IPCmay also induced defense against ischemic injury in kidney through
release of EPO from the kidney (Gardner et al., 2014; Diwanet al., 2008).
Moreover, it is possible that catecholamines may also play a role in limb
IPC-induced renalase upregulation. It has been reported that remote IPC
can lead to increased catecholamines levels in myocardial tissue and
catecholamines can evoke renalase synthesis (Wang et al., 2014a; Li
et al., 2008). In addition, pretreatment with catecholamines can mimic
the effect of preconditioning (Bankwala et al., 1994; De Zeeuw et al.,
Fig. 7. Limb ischemic preconditioning induces renalase via TNFα/NF-κB pathways. Limb ischemic preconditioning (IPC) was delivered by occluding hind limb blood ﬂowwith a tightened
tourniquet around the upper thigh for 6 cycles of 10-min occlusion followed by 10-min release. a. Kidney renalasemRNA changes at different time points after limb IPC. b. Kidney renalase
protein levels at different time points after limb IPC. c. TNFαmRNA at 6 h after limb IPC. d. Serum TNFα level at 6 h after limb IPC. e. Kidney phospho-IκBα (pIκBα) expression at 6 h after
limb IPC with TNFα blocking (Humira), NF-κB blocking (PDTC) or HIF-1α blocking (YC-1). f. Kidney renalase expression 6 h after limb IPC with TNFα blocking (Humira), NF-κB blocking
(PDTC) or HIF-1α blocking (YC-1). All values are presented as means ± SEM (N= 6).⁎P b 0.05 versus Sham; #P b 0.05 versus IPC.
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various molecules/signaling pathways contribute to the reno-
protection after limb IPC and whether they act coordinately to regulate
this response.
In summary, this study reveals an important role of endogenous
renalase in limb IPC-mediated reno-protection against CIN. Limb IPCFig. 8. TNFα preconditioning induces renalase upregulation via NF-κB pathway. TNFα precondit
harvested at 6 h after TNFα preconditioning. HK2 cellswere exposed to TNFα for 6 h, and renala
(Humira), NF-κB blocking (PDTC) or HIF-1α blocking (YC-1), ⁎P b 0.05 versus Sham; #P b 0.0
Renalase expression induced by TNFα with NF-κB blocking (PDTC) or HIF-1α blocking (YC-
different TNFα concentration, ⁎P b 0.05 versus Control (CTL). e. TPCK blocked TNFα induced r
10 ng/l. All the values depicted are mean ± SEM from 3 independent experiments.may exert its beneﬁcial effects through a humoral signaling pathway
by secreting TNFα into the circulation, subsequently activating NF-κB
survival signaling in the kidney. This work provides an insight into the
mechanisms of limb IPC as well as renalase biogenesis, and lays the
groundwork for clinical CIN prevention and treatment with renalase
therapy.ioningwas induced by intravenous injection of TNFα (0.1 μg/kg) in rats. The kidneys were
se expressionwas assessed. a. Renalase expression induced by limb IPCwith TNFα blocking
5 versus IPC; b. Phospho-IκBα (pIκBα) expression at 6 h after TNFα preconditioning. c.
1). ⁎P b 0.05 versus Sham; #P b 0.05 versus TNFα; d. Renalase expression in HK2 under
enalase upregulation in HK2 cells. ⁎P b 0.05 versus Control (CTL); #P b 0.05 versus TNFα
Fig. 9. Low dose of TNFα pretreatment protects against H2O2-induced oxidative injury. HK-2 cells were pretreatedwith vehicle or TNFα (10 ng/ml) for 6 h and thenwere exposed to H202
(300 μm/l) for an additional 12 h. Cells were harvested for measuring LDH release and immunoblot analysis of cleaved caspase-3. a. LDH release; b. cleaved caspase3 expression. ⁎P b 0.05
versus Control (CTL); #P b 0.05 versus TNFα 10 ng/ml. All the value depicted are mean ± SEM from 3 independent experiments.
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